CDH19

Summary

CDH19 (cadherin 19, HGNC:1758) is a protein-coding gene on chromosome 18q22.1, encoding Cadherin-19 (Q9H159). Cadherins are calcium-dependent cell adhesion proteins.

This gene is one of three related type II cadherin genes situated in a cluster on chromosome 18. The encoded protein is a calcium dependent cell-cell adhesion glycoprotein containing five extracellular cadherin repeats. Loss of cadherins may be associated with cancer formation. Alternative splicing results in multiple transcript variants for this gene.

Source: NCBI Gene 28513 — RefSeq curated summary.

At a glance

• GWAS associations: 14
• Clinical variants (ClinVar): 302 total — 1 pathogenic
• MANE Select transcript: NM_021153

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1758
Approved symbol	CDH19
Name	cadherin 19
Location	18q22.1
Locus type	gene with protein product
Status	Approved
Aliases	CDH7
Ensembl gene	ENSG00000071991
Ensembl biotype	protein_coding
OMIM	603016
Entrez	28513

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 9 protein_coding, 1 nonsense_mediated_decay

ENST00000262150, ENST00000454642, ENST00000540086, ENST00000579658, ENST00000580157, ENST00000877570, ENST00000877571, ENST00000877572, ENST00000954985, ENST00000954986

RefSeq mRNA: 2 — MANE Select: NM_021153 NM_001271028, NM_021153

CCDS: CCDS11994, CCDS59325

Canonical transcript exons

ENST00000262150 — 12 exons

Exon	Start	End
ENSE00000950297	66554405	66554524
ENSE00000950298	66551094	66551258
ENSE00000950299	66544719	66544903
ENSE00000950300	66543971	66544224
ENSE00000950301	66534986	66535107
ENSE00000950304	66501083	66505302
ENSE00000995682	66603954	66604090
ENSE00001103287	66568416	66568710
ENSE00001103290	66511568	66511685
ENSE00001103293	66508995	66509246
ENSE00001103299	66529845	66529966
ENSE00003787254	66572010	66572316

Expression profiles

Bgee: expression breadth ubiquitous, 240 present calls, max score 99.43.

FANTOM5 (CAGE): breadth broad, TPM avg 2.9577 / max 379.9191, expressed in 242 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
172297	1.4054	215
172298	0.7568	179
172299	0.5919	173
172301	0.1211	53
172300	0.0601	29
172302	0.0223	8

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
trigeminal ganglion	UBERON:0001675	99.43	gold quality
dorsal root ganglion	UBERON:0000044	99.29	gold quality
olfactory bulb	UBERON:0002264	98.87	gold quality
heart right ventricle	UBERON:0002080	97.90	gold quality
nerve	UBERON:0001021	96.67	gold quality
tibial nerve	UBERON:0001323	96.67	gold quality
myocardium	UBERON:0002349	95.14	gold quality
sural nerve	UBERON:0015488	94.86	gold quality
cardiac muscle of right atrium	UBERON:0003379	94.73	gold quality
pericardium	UBERON:0002407	94.45	gold quality
cardiac atrium	UBERON:0002081	92.84	gold quality
left ventricle myocardium	UBERON:0006566	92.55	gold quality
right atrium auricular region	UBERON:0006631	92.42	gold quality
corpus callosum	UBERON:0002336	90.44	gold quality
lateral globus pallidus	UBERON:0002476	90.11	gold quality
vena cava	UBERON:0004087	89.81	gold quality
heart	UBERON:0000948	88.07	gold quality
substantia nigra pars reticulata	UBERON:0001966	87.11	gold quality
left coronary artery	UBERON:0001626	86.59	gold quality
seminal vesicle	UBERON:0000998	86.55	gold quality
inferior vagus X ganglion	UBERON:0005363	86.26	gold quality
coronary artery	UBERON:0001621	86.17	gold quality
cardiac ventricle	UBERON:0002082	85.89	gold quality
parotid gland	UBERON:0001831	85.73	gold quality
endothelial cell	CL:0000115	85.66	gold quality
mucosa of stomach	UBERON:0001199	85.66	gold quality
inferior olivary complex	UBERON:0002127	85.65	gold quality
heart left ventricle	UBERON:0002084	85.54	gold quality
muscle layer of sigmoid colon	UBERON:0035805	85.37	gold quality
penis	UBERON:0000989	84.82	gold quality

Single-cell (SCXA)

Detected in 9 experiment(s), a significant marker in 8.

Experiment	Marker?	Max mean expression
E-ANND-2	yes	4098.04
E-MTAB-11268	yes	2550.55
E-GEOD-135922	yes	1748.43
E-HCAD-36	yes	1056.76
E-HCAD-11	yes	34.04
E-MTAB-8410	yes	28.79
E-CURD-46	yes	17.64
E-MTAB-9543	no	1476.86
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

141 targeting CDH19, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-33A-5P	99.99	68.62	1055
HSA-MIR-33B-5P	99.99	68.58	1062
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562

Literature-anchored findings (GeneRIF, showing 2)

• Gene expression profiling of Glioblastoma stem-like cells has shown CDH19 to be an exciting new target for drug development and study of glioblastoma multiforme tumorigenesis (PMID:25361488)
• The cadherin protein CDH19 mediates cervical carcinoma progression by regulating AKT/NF-kappaB signaling. (PMID:38052007)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Cdh19	ENSMUSG00000047216
rattus_norvegicus	Cdh19	ENSRNOG00000029841

Paralogs (33): CDH1 (ENSG00000039068), CDH10 (ENSG00000040731), CDH3 (ENSG00000062038), CDHR2 (ENSG00000074276), CDH17 (ENSG00000079112), CDH7 (ENSG00000081138), PCDH11Y (ENSG00000099715), CDHR5 (ENSG00000099834), CDH20 (ENSG00000101542), PCDH11X (ENSG00000102290), CDH23 (ENSG00000107736), CDH9 (ENSG00000113100), CDH6 (ENSG00000113361), CDH26 (ENSG00000124215), CDHR3 (ENSG00000128536), CDH15 (ENSG00000129910), CDH24 (ENSG00000139880), CDH11 (ENSG00000140937), CDH13 (ENSG00000140945), CDH18 (ENSG00000145526), CDHR1 (ENSG00000148600), CDH22 (ENSG00000149654), CDH8 (ENSG00000150394), CDH12 (ENSG00000154162), PCDH1 (ENSG00000156453), DCHS1 (ENSG00000166341), PCDH7 (ENSG00000169851), CDH2 (ENSG00000170558), CDH4 (ENSG00000179242), CDH5 (ENSG00000179776), PCDH9 (ENSG00000184226), DCHS2 (ENSG00000197410), PCDH20 (ENSG00000280165)

Protein

Protein identifiers

Cadherin-19 — Q9H159 (reviewed: Q9H159)

All UniProt accessions (4): Q9H159, F8VVI9, J3KTP3, J3QS15

UniProt curated annotations — full annotation on UniProt →

Function. Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types.

Subcellular location. Cell membrane.

Tissue specificity. Expressed in many tissues, with the exception of uterus.

Domain organisation. Three calcium ions are usually bound at the interface of each cadherin domain and rigidify the connections, imparting a strong curvature to the full-length ectodomain.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9H159-1	1	yes
Q9H159-2	2

RefSeq proteins (2): NP_001257957, NP_066976* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000233	Cadherin_Y-type_LIR	Domain
IPR002126	Cadherin-like_dom	Domain
IPR015919	Cadherin-like_sf	Homologous_superfamily
IPR020894	Cadherin_CS	Conserved_site
IPR027397	Catenin-bd_sf	Homologous_superfamily
IPR039808	Cadherin	Family

Pfam: PF00028, PF01049

UniProt features (22 total): glycosylation site 8, domain 5, splice variant 2, topological domain 2, signal peptide 1, propeptide 1, chain 1, sequence conflict 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H159-F1	78.14	0.44

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (8): 57, 74, 419, 437, 508, 515, 516, 534

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-9764302	Regulation of CDH19 Expression and Function
R-HSA-1500931	Cell-Cell communication
R-HSA-418990	Adherens junctions interactions
R-HSA-421270	Cell-cell junction organization
R-HSA-446728	Cell junction organization
R-HSA-9759476	Regulation of Homotypic Cell-Cell Adhesion
R-HSA-9764260	Regulation of Expression and Function of Type II Classical Cadherins

MSigDB gene sets: 227 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_MCMV_INFECTION_UP, BENPORATH_ES_WITH_H3K27ME3, ASTON_MAJOR_DEPRESSIVE_DISORDER_DN, STOSSI_RESPONSE_TO_ESTRADIOL, GOBP_CALCIUM_DEPENDENT_CELL_CELL_ADHESION, REACTOME_ADHERENS_JUNCTIONS_INTERACTIONS, GOBP_CELL_CELL_ADHESION, GOBP_CELL_JUNCTION_ORGANIZATION, HELLER_HDAC_TARGETS_SILENCED_BY_METHYLATION_UP, AACTTT_UNKNOWN, chr18q22, SABATES_COLORECTAL_ADENOMA_DN, GOBP_CELL_JUNCTION_ASSEMBLY, GOBP_ADHERENS_JUNCTION_ORGANIZATION, VECCHI_GASTRIC_CANCER_EARLY_DN

GO Biological Process (9): cell morphogenesis (GO:0000902), cell-cell junction assembly (GO:0007043), homophilic cell-cell adhesion (GO:0007156), calcium-dependent cell-cell adhesion (GO:0016339), cell migration (GO:0016477), adherens junction organization (GO:0034332), cell-cell adhesion mediated by cadherin (GO:0044331), cell adhesion (GO:0007155), cell-cell adhesion (GO:0098609)

GO Molecular Function (4): calcium ion binding (GO:0005509), beta-catenin binding (GO:0008013), cadherin binding (GO:0045296), metal ion binding (GO:0046872)

GO Cellular Component (4): plasma membrane (GO:0005886), adherens junction (GO:0005912), catenin complex (GO:0016342), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
Regulation of Expression and Function of Type II Classical Cadherins	1
Cell-cell junction organization	1
Cell junction organization	1
Cell-Cell communication	1
Adherens junctions interactions	1
Regulation of Homotypic Cell-Cell Adhesion	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell-cell adhesion	3
cell-cell junction organization	2
anatomical structure morphogenesis	1
cell junction assembly	1
cell motility	1
cellular process	1
cell adhesion	1
metal ion binding	1
protein binding	1
cell adhesion molecule binding	1
cation binding	1
membrane	1
cell periphery	1
cell-cell junction	1
extrinsic component of plasma membrane	1
plasma membrane protein complex	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1024 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CDH19	CDH15	P55291	668
CDH19	CDH2	P19022	650
CDH19	CDH10	Q9Y6N8	632
CDH19	CDH6	P55285	576
CDH19	CDH4	P55283	519
CDH19	SMARCA4	P51532	497
CDH19	CTNNB1	P35222	464
CDH19	CDH8	P55286	461
CDH19	CDH3	P22223	460
CDH19	CDH12	P55289	459
CDH19	PCDH1	Q08174	453
CDH19	SOX10	P56693	441
CDH19	PCDH15	Q96QU1	430
CDH19	CDH18	Q13634	425
CDH19	CDH9	Q9ULB4	422

IntAct

4 interactions, top by confidence:

A	B	Type	Score
CDH19	H2BC12L	psi-mi:“MI:0915”(physical association)	0.400
CDH19	HIST2H2BF	psi-mi:“MI:0915”(physical association)	0.400
CDH19	TADA2A	psi-mi:“MI:0914”(association)	0.350

BioGRID (50): CDH19 (Synthetic Lethality), FBXO45 (Affinity Capture-MS), CSRP2BP (Affinity Capture-MS), MARK1 (Affinity Capture-MS), YEATS2 (Affinity Capture-MS), KLHDC3 (Affinity Capture-MS), MYCBP2 (Affinity Capture-MS), ZZZ3 (Affinity Capture-MS), TADA2A (Affinity Capture-MS), MARK3 (Affinity Capture-MS), DDX11 (Affinity Capture-MS), MBIP (Affinity Capture-MS), C15orf39 (Affinity Capture-MS), TADA3 (Affinity Capture-MS), TPP2 (Affinity Capture-MS)

ESM2 similar proteins: A0A8M2BIB6, F1QSQ0, F8W3X3, H2EQR6, O35902, O54800, O55111, O93319, P32926, P33545, P55280, P55285, P55286, P55287, P55288, P55289, P55292, P55849, P55850, P70407, P70408, P79995, P97291, P97326, Q01107, Q02413, Q02487, Q08554, Q08DJ5, Q13634, Q14126, Q14574, Q28060, Q3SWX5, Q5DWV1, Q5RJH3, Q61495, Q68SP4, Q6W3B0, Q7TMD7

Diamond homologs: A0A8M2BIB6, B0KW95, B2KI42, B4USZ0, F1PAA9, F1QSQ0, O02840, O35902, O54800, O55075, O55111, O93319, P08641, P09803, P10287, P10288, P12830, P15116, P19022, P19534, P19535, P20310, P22223, P24503, P30944, P32926, P33145, P33146, P33147, P33148, P33150, P33151, P33152, P33545, P39038, P55280, P55283, P55284, P55285, P55286

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
calcium(2+)	“up-regulates activity”	CDH19	“chemical activation”
CDH19	“up-regulates activity”	CTNNB1	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

302 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	218
Likely benign	21
Benign	47

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
146120	GRCh38/hg38 18q21.33-22.1(chr18:63846473-66558774)x1	Pathogenic

SpliceAI

4335 predictions. Top by Δscore:

Variant	Effect	Δscore
18:65809995:GTGG:G	donor_gain	1.0000
18:65809999:GT:G	donor_loss	1.0000
18:65810000:TAA:T	donor_loss	1.0000
18:65814438:T:TA	acceptor_gain	1.0000
18:65814600:GACAG:G	donor_gain	1.0000
18:65814601:ACAG:A	donor_loss	1.0000
18:65814602:CAGGT:C	donor_loss	1.0000
18:65814603:AG:A	donor_loss	1.0000
18:65814604:GGT:G	donor_loss	1.0000
18:65814605:GTAAA:G	donor_loss	1.0000
18:65814606:T:A	donor_loss	1.0000
18:65822246:GAA:G	donor_gain	1.0000
18:65822247:AA:A	donor_gain	1.0000
18:65822247:AAGTA:A	donor_loss	1.0000
18:65822248:AG:A	donor_loss	1.0000
18:65822249:G:GG	donor_gain	1.0000
18:65822250:TAAGT:T	donor_loss	1.0000
18:65824636:T:G	acceptor_gain	1.0000
18:65824639:CACAG:C	acceptor_loss	1.0000
18:65824640:A:AG	acceptor_gain	1.0000
18:65824640:ACAG:A	acceptor_gain	1.0000
18:65824640:ACAGG:A	acceptor_gain	1.0000
18:65824641:C:G	acceptor_gain	1.0000
18:65824641:CAG:C	acceptor_loss	1.0000
18:65824642:A:AG	acceptor_gain	1.0000
18:65824642:AG:A	acceptor_gain	1.0000
18:65824642:AGG:A	acceptor_gain	1.0000
18:65824643:G:A	acceptor_gain	1.0000
18:65824643:G:GA	acceptor_gain	1.0000
18:65824643:GGG:G	acceptor_gain	1.0000

AlphaMissense

5141 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
18:66529900:G:T	P468H	0.995
18:66534997:G:T	A442D	0.995
18:66544828:T:G	D284A	0.993
18:66551252:A:T	I206K	0.993
18:66554500:G:T	A172E	0.992
18:66509238:C:G	A529P	0.991
18:66544732:A:T	V316D	0.991
18:66544834:T:G	D282A	0.991
18:66551108:G:T	P254H	0.991
18:66551187:C:G	D228H	0.991
18:66568463:A:G	F148S	0.991
18:66509126:A:G	L566P	0.990
18:66551192:G:T	A226D	0.989
18:66568462:G:C	F148L	0.989
18:66568462:G:T	F148L	0.989
18:66568464:A:G	F148L	0.989
18:66568478:T:G	D143A	0.989
18:66509237:G:T	A529D	0.988
18:66511666:G:T	A493E	0.988
18:66544828:T:A	D284V	0.988
18:66551252:A:C	I206R	0.988
18:66551258:C:A	G204V	0.988
18:66551258:C:T	G204E	0.988
18:66554425:A:G	F197S	0.988
18:66554515:A:T	V167D	0.988
18:66568616:C:T	G97D	0.988
18:66534998:C:G	A442P	0.987
18:66544840:G:T	A280E	0.987
18:66551144:A:T	V242E	0.987
18:66551193:C:G	A226P	0.987

dbSNP variants (sampled 300 via entrez): RS1000002045 (18:66524394 A>G), RS1000010571 (18:66585441 A>G), RS1000017685 (18:66564811 C>T), RS1000030626 (18:66577537 C>G), RS1000049159 (18:66591172 G>A), RS1000056036 (18:66524636 A>T), RS1000099518 (18:66554647 C>A,G,T), RS1000105089 (18:66513220 A>G), RS1000105673 (18:66555695 G>T), RS1000120275 (18:66591310 A>G), RS1000186247 (18:66590044 A>G,T), RS1000253944 (18:66574320 T>A,G), RS1000268874 (18:66573720 A>G), RS1000273512 (18:66561597 TG>T), RS1000285078 (18:66501961 A>G)

Disease associations

OMIM: gene MIM:603016 | disease phenotypes:

GenCC curated gene-disease

Mondo (2): breast ductal adenocarcinoma (MONDO:0005590), primary ovarian failure (MONDO:0005387)

Orphanet (1): NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

14 associations (top):

Study	Trait	p-value
GCST001776_8	Cardiac Troponin-T levels	6.000000e-06
GCST002178_6	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU)	7.000000e-06
GCST002587_30	Blood pressure (smoking interaction)	3.000000e-07
GCST003808_4	Non-response to selective serotonin reuptake inhibitors and depression	2.000000e-06
GCST004639_5	Prudent dietary pattern	2.000000e-06
GCST004904_201	Body mass index	3.000000e-08
GCST005666_1	Fractional excretion of metabolites in chronic kidney disease	3.000000e-08
GCST006427_24	Depression in smokers	4.000000e-06
GCST006941_49	Irritable mood	1.000000e-08
GCST007576_49	Chronotype	1.000000e-08
GCST009391_2085	Metabolite levels	9.000000e-07
GCST009391_534	Metabolite levels	4.000000e-06
GCST010988_9	Adult body size	4.000000e-11
GCST011140_1	Glucagon levels in response to oral glucose tolerance test (decremental area under the curve for 0-30 minutes)	1.000000e-06

EFO canonical traits (12, from GWAS)

EFO ID	Trait name
EFO:0005043	cardiac troponin T measurement
EFO:0006335	systolic blood pressure
EFO:0006526	pack-years measurement
EFO:0005658	response to selective serotonin reuptake inhibitor
EFO:0008111	diet measurement
EFO:0004340	body mass index
EFO:0005116	urinary metabolite measurement
EFO:0009594	irritability measurement
EFO:0008328	chronotype measurement
EFO:0010373	phosphatidylcholine 32:1 measurement
EFO:0010528	quinolinic acid measurement
EFO:0008463	glucagon measurement

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

15 total (human), top 15 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, decreases methylation	3
Aflatoxin B1	decreases methylation, increases methylation	2
bisphenol A	increases methylation	1
trichostatin A	increases expression	1
pentanal	decreases expression	1
CGP 52608	affects binding, increases reaction	1
2-palmitoylglycerol	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Benzo(a)pyrene	affects methylation	1
Copper	affects cotreatment, increases expression	1
Doxorubicin	decreases expression	1
Nickel	decreases expression	1
Silicon Dioxide	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Okadaic Acid	decreases expression	1

Clinical trials (associated diseases)

86 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT03414970	PHASE3	ACTIVE_NOT_RECRUITING	Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT00461344	PHASE2	TERMINATED	Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT07499999	PHASE2	NOT_YET_RECRUITING	Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT02912104	PHASE1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT03178695	PHASE1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT04815213	PHASE1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	PHASE1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	PHASE1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT00637364	PHASE1/PHASE2	SUSPENDED	High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain
NCT02779855	PHASE1/PHASE2	COMPLETED	Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT01753908	EARLY_PHASE1	COMPLETED	Broccoli Sprout Extract in Treating Patients With Breast Cancer
NCT01796041	EARLY_PHASE1	COMPLETED	Intraoperative Imaging of Breast Cancer With Indocyanine Green
NCT01208974	Not specified	ACTIVE_NOT_RECRUITING	Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction
NCT01875198	Not specified	TERMINATED	Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer
NCT03543397	Not specified	UNKNOWN	MRI in Ductal Carcinoma in Situ (DCIS)
NCT03834532	Not specified	COMPLETED	Living Well After Breast Surgery
NCT00948857	PHASE2/PHASE3	TERMINATED	Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
NCT04031456	PHASE2/PHASE3	RECRUITING	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT02043743	PHASE1/PHASE2	UNKNOWN	Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure
NCT02062931	PHASE1/PHASE2	UNKNOWN	Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
NCT02151890	PHASE1/PHASE2	COMPLETED	Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure
NCT02372474	PHASE1/PHASE2	COMPLETED	It is a Real The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure
NCT02603744	PHASE1/PHASE2	UNKNOWN	Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)
NCT02644447	PHASE1/PHASE2	COMPLETED	Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF
NCT03069209	PHASE1/PHASE2	UNKNOWN	Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)
NCT03985462	PHASE1/PHASE2	WITHDRAWN	Very Small Embryonic-like Stem Cells for Ovary
NCT04009473	PHASE1/PHASE2	UNKNOWN	Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation